Evolution of the Average Target: DSM-Firmenich

Evolution of the Target Price: DSM-Firmenich

Changes in Analyst Recommendations: DSM-Firmenich

88241a871984dfb5952def02ad0d89dd.v15vRpzeXzM1nnTo8EBktXhdi1Tt5rSAmom7Iza-zI0.1AECf-iTLmtU_TiSpzU33hZq2GWv0efqwsTod1yOtMvFEyQe8esTenb0IQ~002cb5787d40425b54a256323ca212d7
08-18 KBC Securities Downgrades DSM-Firmenich to Hold MT
08-12 Kempen Downgrades DSM-Firmenich to Sell, Boosts PT MT
08-10 Oddo BHF Boosts DSM-Firmenich PT, Maintains Outperform Rating MT
08-06 Equita SIM Downgrades DSM-Firmenich to Hold, Raises PT MT
07-30 DSM-Firmenich: Volume inflection validated the strategy Alphavalue
06-19 AlphaValue/Baader Europe Downgrades DSM-Firmenich to Reduce, Lifts PT MT
06-09 AlphaValue/Baader Europe Upgrades DSM-Firmenich to Add, Lifts PT MT
06-08 Goldman Sachs Downgrades DSM-Firmenich to Sell, Cuts PT MT
05-22 AlphaValue/Baader Europe Downgrades DSM-Firmenich to Reduce, Lifts PT MT
05-22 Swiss stocks - Factors to watch on May 22 RE
05-06 DSM-Firmenich: Volumes deliver, margin to follow Alphavalue
04-28 KBC Securities weighs in on DSM-Firmenich divestment Zonebourse
03-18 KBC Securities Still Positive on DSM-Firmenich Zonebourse
03-17 Sulfur and methanol prices soar on Middle East conflict Alphavalue
03-13 DSM-Firmenich ready to step up the pace and hit its mid-term targets Zonebourse
03-12 DSM-Firmenich: The story moves from restructuring to delivery Alphavalue
03-11 Kempen Downgrades DSM-Firmenich to Neutral, Cuts PT MT
03-04 Middle East tensions intensify pessimism in chemicals Alphavalue
02-26 AlphaValue/Baader Europe Adjusts Rating, Estimates for DSM-Firmenich on Sale of Animal Nutrition, Health Unit MT
02-25 DSM-Firmenich: ANH Divestment at a Discount May Unlock Growth Potential Alphavalue
02-13 Kepler Cheuvreux Downgrades DSM-Firmenich to Hold, Cuts PT MT
02-12 DSM-Firmenich: Profitability disappoints in FY25 Alphavalue
02-09 DSM-FIRMENICH : Jefferies reaffirms its Buy rating ZD
12-30 Berenberg Reduces DSM-Firmenich PT, Keeps Buy Rating MT
12-30 Berenberg Expects DSM-Firmenich to Retain Minority Stake in Vitamins Business Amid 'Protracted' Deal Talks MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+7.53%
+20.95%
+3.69%
+36.84%
+6.93%
+22.9%
+21.79%
+1.72%
Average +15.29%
Weighted average by Cap. +11.17%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
90.76EUR
Average target price
92.32EUR
Spread / Average Target
+1.72%
High Price Target
106.00EUR
Spread / Highest target
+16.79%
Low Price Target
67.00EUR
Spread / Lowest Target
-26.18%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

KBC Securities
Kempen
ODDO BHF
Equita SIM
alphavalue Théodore Duval-Segard
AlphaValue/Baader Europe
Goldman Sachs
Kepler Cheuvreux
JEFFERIES Chris Counihan
Berenberg Bank
Barclays
Deutsche Bank Research
BNP Paribas
Stifel Nicolaus
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
90.76EUR
Average target price
92.32EUR
Spread / Average Target
+1.72%

Quarterly revenue - Rate of surprise